Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Cutting-Edge Neuroimaging for Functional Brain Network Evaluation in Cancer Patients

Project description

Early detection of gliomas and brain metastases is made possible by AI

Research in cancer neuroscience has revealed that detrimental brain networks contribute to tumour aggressiveness. However, no imaging tool is currently available that effectively translates these findings into clinical metrics. The ERC-funded CONNECT project will establish functional connectivity MRI (fcMRI) as a clinical tool for large-scale brain networks. It will develop AI methods to detect and quantify anomalies in patients with glioma and those at risk of brain metastases. It will create a reference database of healthy brain connectivity profiles. The project’s findings will link fcMRI anomalies to structural changes and genomic data to enable early detection and improve patient care in oncologic brain diseases and potentially extend to neurodegenerative disorders.

Objective

The overall goal of CONNECT is to establish functional connectivity MRI (fcMRI) as a quantitative imaging tool of large-scale brain networks, ready for clinical application. Cancer neuroscience has demonstrated that harmful brain networks drive tumor aggressiveness, yet no imaging tool translates these findings into clinical metrics.
With CONNECT, I aim to develop AI-powered fcMRI anomaly detection, mapping and quantification in individual patients based on normative reference data, then establish the structural and neuropathological underpinnings of detected fcMRI anomalies and finally demonstrate their clinical potential in patients with oncologic brain diseases.
To achieve this, I will create a reference database of healthy connectivity profiles by leveraging existing fMRI datasets, integrating variability across demographics and MRI protocols to ensure broad applicability. Based on this database, I will develop AI-powered tools for fcMRI anomaly detection at speed and scale. To demonstrate biological validity and clinical utility, CONNECT will establish two cohorts undergoing repeated MRI: patients with glioma and patients at risk for brain metastases from breast or lung cancer. To confirm biological validity, CONNECT will relate detected fcMRI anomalies to structural connectivity changes and transcriptomic findings from connectivity-guided tumor sampling. To demonstrate clinical utility, CONNECT will demonstrate fcMRI’s potential for early detection and prognostication in these patients.
CONNECT represents a significant leap forward by transforming fcMRI from a promising research tool into an accessible technology for clinical application, thereby translating cancer neuroscience insights into improved patient care. This approach has great potential to extend to neurodegenerative diseases, amplifying its impact across neurological disorders.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-COG

See all projects funded under this call

Host institution

LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Net EU contribution
€ 0,00
Address
GESCHWISTER SCHOLL PLATZ 1
80539 Planegg
Germany
Region
Bayern Oberbayern München, Kreisfreie Stadt
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 1 997 992,00

Beneficiaries (2)